SCHEMBL30765613

SCHEMBL30765613

CCCCOC(=O)Cn1c(-c2ccc(O)cc2)ncc(NCCCc2ccccc2)c1=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ELANE P08246 14/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM4E B2RXH2 1/20 0.39
ASPH Q12797 1/20 0.39
RIOX2 Q8IUF8 1/20 0.39
KDM8 Q8N371 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765630 0.90 GAA (0.47) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30766150 0.89 GAA (0.52) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765463 0.86 GAA (0.44) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765524 0.86 GAA (0.44) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765457 0.86 ELANE (0.43) ELANEKDM4EASPHRIOX2KDM8
SCHEMBL30765667 0.85 GAA (0.56) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765817 0.85 GAA (0.42) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765958 0.84 GAA (0.42) GAAL3MBTL1ELANETSHR
SCHEMBL30765606 0.83 MEN1 (0.44) GAAL3MBTL1MEN1KMT2ALMNA
SCHEMBL30765714 0.82 MEN1 (0.43) GAAL3MBTL1MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed